- TRADE NAME: Uptravi (Actelion)
- INDICATIONS: Pulmonary arterial hypertension
- CLASS: Prostacyclin receptor agonist
- HALF-LIFE: <3 hours
- FDA APPROVAL DATE: 12/21/2015
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Gemfibrozil, Strong CYP2C8 inhibitors - PREGNANCY: No data available
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see two reviews of selexipag in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 12/02/2023
